Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer.

The majority of patients with newly diagnosed metastatic prostate cancer (PC) initially respond to androgen deprivation therapy (ADT) and are classified as metastatic castration-sensitive PC (mCSPC).